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Abstract 
Introduction:  The need for evidence based 
recommendations regarding biomedical approaches to 
autism was felt in view of the significant number of 
autistic children presenting within the Child Development 
Assessment Unit, Malta and the interest shown in these 
approaches by their families and local nongovernmental 
organisations. 
Aim: To establish the medical basis of biomedical 
approaches to treating autism, by establishing which of 
these approaches are of reported proven efficacy, 
effectiveness and safety and hence offer recommendations 
for their use.  
Methods: An electronic literature search was carried out 
for supporting evidence-based biomedical approaches in 
autism, particularly mainstream authoritative national 
guidelines. 
Results: No strong recommendation was found to support 
any of the biomedical approaches to autism addressed in 
10 authoritative national guidelines from 1999 to 2011. 
The evidence and recommendations were against 
using chelation, immunoglobulin therapy, secretin, 
amantadine, antifungal/yeast therapies, naltrexone, 
dimethylglycine, vancomycin, digestive enzyme 
supplements and donepezil.  
Melatonin for sleep disturbances and to a lesser degree, 
Omega-3 fatty acids for hyperactivity had enough 
support to consider their use in autism. The 
recommendations for gluten/casein diets, and Vitamin 
B6/magnesium were mostly either indeterminate or 
negative. Iron, vitamin C, piracetam, pentoxifylline, 
ketogenic diets, L-carnosine and hyperbaric oxygen 
therapy could not be safely recommended.  
Conclusion: The evidence-based literature does 
not support most biomedical approaches to autism. 
There is limited support for melatonin and Omega-3 
use. 
 
 
 
Keywords 
Autism-treatment-guidelines 
 
 
 
 
 
 
 
 
John Mary Farrugia MSc, MRCP (UK) 
Child Development Assessment Unit, CDAU, St. Luke’s 
Hospital, Gwardamagia, Maltas 
Email: john.m.farrugia@gov.mt 
 
 
 
 
 
 
 
Introduction 
Autism/Autism Spectrum Disorder (ASD) is a 
spectrum of neurodevelopmental disorders diagnosed 
on the basis of a behavioural phenotype in children 
presenting before 3 years of age showing impairment 
in socialization, communication as well as restricted, 
repetitive and stereotyped patterns of behaviour, 
interests, and activities (DSM-IV-TR).
1
 
The reported current rate of diagnosis of autism 
may be as high as 1 in every 100 children.
2
 26% of all 
children first presenting to the author within the Child 
Development Assessment Unit, CDAU St. Luke's 
Hospital, Malta present with communication 
difficulties. 27% of these meet the DSM-IV-TR 
criteria for Autistic Disorder.   
An ever increasing number of parents of children 
with autism presenting within the CDAU, as well as 
local nongovernmental organisations are interested in 
biomedical approaches to autism besides the 
conventional approaches of speech and language 
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therapy, occupational therapy, and early educational 
intervention.  
It is felt that local medical professionals should be 
knowledgeable about such biomedical approaches and thus 
be able to provide parents with unbiased evidence-based 
opinions. This prompted the review being presented here. 
Aim 
To establish the medical basis of biomedical 
approaches to treating autism, by establishing which of 
these approaches are of reported proven efficacy, 
effectiveness and safety and hence offer recommendations 
for their use.  
Objectives 
To summarise the established authoritative national 
recommendations addressing biomedical approaches to 
autism published for the period 1999-2011, and set forth 
recommendations regarding the use of specific biomedical 
approaches. 
Method 
An electronic search was made for the literature 
supporting evidence-based biomedical approaches in 
autism. This was mainly through using internet searches of 
terms "biomedical treatments in autism"/ "therapy in 
autism"/"management of autism spectrum disorders" 
and related search terms on Google, and a wide 
expanse of medical websites including PubMed, 
MERK,  MedlinePlus, UpToDate, DL+, ScienceDirect, 
Medscape, MD Consult, MeSH, WebMD, 
HealthCentral, WD Medical Dictionary, 
OpenMED@NIC, CureResearch, Diseases database, 
WHO, Mayoclinic, NIH, bmj Group, JAMA, NEJM, 
journal watch, Ovid MEDLINE, Oxford Journals and 
Springer. The focus was on the management, treatment 
or therapy in autism. Priority was given primarily to 
mainstream authoritative national guidelines 
addressing biomedical approaches to autism published 
from 1999 to 2011. Specific papers and international 
recommendations regarding hyperbaric oxygen 
therapy for autism were also focused upon for the 
period 2009-2011.  
Results 
Authoritative national guidelines and sources 
addressing biomedical approaches to autism: 1999 - 
2011 
Ten authoritative national guidelines addressing 
biomedical approaches to autism were located. Eight 
were published between 1999-2011.
3,4,5,6,7,8,9,10
 Three 
guidelines addressing  hyperbaric oxygen therapy, 
were published between 2009-2011.
3,11,12
 
 
 
 
2011 USA 
AHRQ3 
2008 
New 
Zealand4 
2007 
USA 
AAP
5 
2007 
UK 
SIGN
6 
2006 
Spain7 
2004 
Australia8 
2003 
Canada9 
1999 
USA
10
 
 
 
Melatonin + ++ ++ ++ -    
Omega-3 fatty acids + - +      
gluten/casein free diets 0 - 0 0 - 0 - - 
Iron +        
Vitamin B6 and magnesium + 0 - 0 - + - - 
Vitamin C   +      
Amantadine /antiviral agents - - - -     
Vancomycin    -     
Immunoglobulin 
- 
 
- 0  -  - -- 
Dimethylglycine - - -  -    
Naltrexone  -   - -   
Antifungal/ yeast   -  - - 0 - 
Secretin - - - - - - - - 
Chelation - -- --  -    
Table 1  Relative recommendations of authoritative national guidelines addressing biomedical approaches to autism: 1999 - 
2011:  
++  Relatively good support for (but still not licensed),   
+  Limited/weak support for, or guarded recommendation, 
 0  No recommendation for/against,  
-  Evidence/recommendation against, 
-  Strong evidence/ recommendation against: dangerous. 
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Table 1 indicates the relative recommendations of each 
national authority vis-à-vis specific biomedical approaches 
to autism, as reported by their respective published 
guidelines. Besides the data shown, the 2011 USA AHRQ 
guidelines also singularly include recommendations on 
piracetam (with risperidone), pentoxifylline (with 
risperidone), ketogenic diets, and L-carnosine (all with + 
limited/weak support for or guarded recommendation); 
cholinesterase inhibitors (donepezil), and digestive enzyme 
supplements (Peptizyde) (both with - negative 
evidence/recommendation). These guidelines also report 
"some promise for future research" for melatonin and 
omega-3 fatty acids.
3
 The USA AAP also noted similar 
promise of omega 3 fatty acids for hyperactivity in autistic 
children.
5 
 
Table 2 indicates the relative support of authoritative 
inter/national guidelines specifically addressing hyperbaric 
oxygen therapy in autism. 
 
 
 
2011: USA: 
AHRQ
3
 
2011: European 
Committee for 
Hyperbaric 
Medicine 
(ECHM).
11
 
2009: UHMS 
Position paper
12
 
+ - - 
Table 2  Relative recommendations of authoritative guidelines 
addressing hyperbaric oxygen therapy in autism:  
+     Limited support for,  
-      Evidence/recommendation against 
 
Discussion  
It is notable that the primary focus of all available 
guidelines concerning therapies in autism is not on 
biomedical treatments but on the conventional medical, 
allied medical, multidisciplinary educational and 
behavioural management approaches to this condition. 
This is understandable as the conventional diagnosis of 
autism is basically defined as a behavioural phenotype and 
not by specific biomedical physiological parameters. 
Moreover, most of the guidelines remark that despite the 
ever increasing popularity of biomedical approaches 
amongst parents of children with autism, varying from 11 - 
70% of children,
 13
 the published evidence for these 
approaches is limited. In fact, the strongest evidence for or 
against any medical approach is present in mainstream 
medical treatments in which pharmaceutical companies 
have an interest and provide funding for such studies.
3
 
Thus, risperidone and aripiprazole have the strongest 
support for their indicated use in autism and are 
recommended for the control of irritability, with a 
cautionary note about their potential harm of weight 
gain, sedation, extrapyramidal effects and 
hyperprolactinaemia. Risperidone and aripiprazole are 
in fact the only drugs licensed and approved by the 
FDA (US Food and Drug Administration) for the 
treatment of irritability in children with autism.
3
 
This review focused on the limited sections of these 
guidelines discussing published evidence and offering 
recommendations regarding the biomedical 
approaches towards autism. 
 
Chelation: dangerous 
The strongest evidence and recommendations that 
these guidelines give are actually negative ones 
against chelation therapy in autism, the American 
Association of Pediatrics
5
 and the New Zealand 
Ministry of Health
4
 stressing on the serious risks of 
renal damage and mortality apart from the evidence 
against its effectiveness in autism in all of the four 
guidelines which address the issue. (2011 USA 
AHRQ
3
, 2008 New Zealand
4
, 2007 AAP
5
 and 2006 
Spain
7
).  
Biomedical approaches advocate the use of 
intravenous or oral chelation therapy on the purported 
basis that heavy metal poisoning due to mercury is a 
cause of the symptoms of autism.
14
 There is no 
evidence to support this claim, nor the association of 
mercury and thiomersal in vaccines and the 
development of autism.
5
 The 2010 CHildhood Autism 
Risks from Genetics and Environmental CHARGE 
study, showed no difference in total blood mercury 
levels in 249 children with autism compared to 143 
controls.
15
 Chelation therapy is licensed by the FDA 
for lead poisoning but not for mercury poisoning.
16
 
The FDA strongly cautions against the use of chelation 
therapy for unapproved indications like autism, in 
view of the risks of "dehydration, kidney failure and 
even death".
17
 Three deaths have been reported in the 
USA, associated with hypocalcaemia from chelation 
therapy.
18
 One of these children was a 5 year old child 
being treated with intravenous EDTA for autism. In 
2008 the US National Institute of Mental Health 
(NIMH) actually withdrew its support for a study on 
chelation in view of the absence of clear evidence of 
the effectiveness of chelation and its associated risks.
19
 
Two years later the FDA also warned against over-the-
counter chelating agents being sold on-line
.17
  
 
Secretin: ineffective 
Secretin is the single most biomedical therapy 
which has consistently been reported to show no 
effectiveness in autism and have recommendations 
against its use throughout all eight available 
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authoritative guidelines. The senior author of the last 
guidelines published, those of the US AHRQ feels that 
"this is the final word"
20
 on the ineffectiveness of secretin. 
After anecdotal reports of its use and its popularity 
amongst biomedical practitioners it has been extensively 
studied and found to be ineffective in autism. There is 
criticism that this illustrates how so much effort and 
resources may be spent by individual families as well as 
the medical community on an approach which in the end 
proves to be ineffective. 
 
Melatonin for sleep difficulties 
The latest four guidelines published, generally report 
relatively good support for the use of melatonin to 
alleviate sleep disturbances in children with autism.
3,4,5,6
 In 
fact, this seems the only biomedical approach to be 
supported by mainstream medical literature as well as 
being strongly promoted by biomedical practitioners.
21
 
Children with ASD have been reported to show 
abnormalities of melatonin regulation.
22,23
 Melatonin has 
been shown to be effective in improving onset of sleep in 
children with neurodevelopmental disabilities in 
general
24,25
 and specifically in those with ASD.
26
 However, 
the effect size may not be as appreciable as some claim. In 
2011 the 'Melatonin for sleep disturbance in neuro-
developmental disorders' study, MENDS, reported that 
children (who included those with autism) given melatonin 
at bedtime slept from as little as 15 minutes to 60 minutes 
longer than their controls.
27
 It is usually recommended 
after behavioural approaches to sleep disturbance have 
been introduced and failed. Though unlicensed for children, 
the British National Formulary for Children (BNFC) 
suggests that clinical experience indicates it may be of 
value, cautioning that it should be started and monitored 
by a specialist with the need to continue medication being 
reviewed every 6 months - the long-term circadian and 
hormonal effects being undefined.
28
 The Martindale cites a 
report that there may be increased seizure activity when on 
melatonin,
29
 and that it is not to be used in hepatic 
impairment.
30
 Being an unlicensed medication the 
information that is available about its effectiveness and 
safety is limited.
4
 
 
Gluten/casein-free GFCF diets: Difficult to establish 
effectiveness in autism 
None of the guidelines supported the use of these diets 
in autism: four state that there is no 
evidence/recommendation for or against these diets, 
another four presenting evidence/recommendations against 
(Table 1).  
 A Cochrane review in 2008
31
 had concluded that the 
current evidence was poor and called on the need for good 
quality RCTs (random controlled trials). A 2009 review by 
Mulloy A et al  concluded that "the current corpus of 
research does not support the use of GFCF diets in the 
treatment of ASD" (Autism Spectrum Disorders).
32
 
Controlled dietary studies are generally difficult and 
expensive to carry out. There were two such studies in 
2010: The ScanBrit study published by Whiteley was a 
randomised controlled, single-blind study suggesting 
that "dietary intervention may positively affect 
developmental outcome for some children diagnosed 
with ASD." However, the paper acknowledges the 
limitation of the study "in the absence of a placebo 
condition."
33
 The second study in 2010 was presented 
at the 9
th
 Annual International Meeting For Autism 
Research (IMFAR) by Hyman S and Stewart PA.
34
 It 
was a well-controlled double blind, placebo controlled 
challenge study using gluten and casein free diets. 
After a strict GFCF diet for 4 weeks preschool autistic 
children were given weekly challenges of wheat or 
milk, both, or neither over 12 weeks, the challenges 
being identical in taste and texture. There were 14 
successful participants. There were no statistically 
significant changes in objective and 
parent/teacher/observer outcomes. Though the sample 
size was small it was well-controlled.  
These diets may be associated with decreased bone 
mass and inadequate vitamin D, calcium and protein 
intake and thus merit monitoring.
35
  
 
Omega-3 fatty acids: some limited evidence 
Evidence, albeit limited, is presented by the two 
last US guidelines (2011 AHRQ, 2007 AAP) to 
support the use of Omega-3 fatty acids.
3,5
 The 2008 
New Zealand guideline reports that omega-3 fatty 
acids are unlikely to be useful.4 The former guidelines 
refer to a sound pilot RCT of omega-3 fatty acids 
supplementation in children with autism which 
indicated a small, non-significant trend towards benefit 
in the hyperactivity and stereotypy subscales.
36
 A 
similar effect on hyperactivity was also reported in 
another recent pilot RCT.
37
 It is concluded that there is 
some early promise for future research in the use of 
omega-3 fatty acids in autism. However, the consensus 
is that there is a need for large well-conducted 
randomised controlled trials that examine both high 
and low functioning individuals with ASD, and that 
have longer follow-up periods.
38
 
 
Vitamin B6 and magnesium: limited evidence for 
All eight guidelines address this biomedical 
approach. The 2011 AHRQ and 2004 Australian 
guidelines present some limited evidence to support 
this.
3,8
 The 2008 New Zealand and 2007 Scottish 
guidelines give no recommendations against or in 
favour,
4,6
 while the other four give 
evidence/recommendations against their use in 
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autism.
5,7,9,10 
Megadoses of Vitamin B6 (>100mg/day) may 
cause neuropathy.
35,39 
 
 
Other approaches which are not recommended in view 
of lack of evidence of effectiveness 
 
Immunoglobulin treatment 
Only the 2007 AAP guideline indicates that there is no 
recommendation for or against this treatment.
5
 Five other 
guidelines are against with the 1999 New York State 
Department of Health guideline strongly recommending 
against in view of the absence of evidence showing 
effectiveness, and the associated risks of transmitting 
blood born infections.
3,4,7,9,10
 
 
Anti-fungal/yeast treatment 
Though the 2003 Canadian guidelines had no 
recommendation for or against anti-fungal treatment four 
other guidelines including the 2007 AAP ones recommend 
against its use in autism.
9,5,7,8,10
 
 
Amantadine (antiviral), dimethylglycine (neuroinhibitor), 
naltrexone (opioid antagonist) 
These have been addressed by four of the guidelines 
and recommendations are against their use.
3,4,5,6
 
 
Vancomycin, peptizyde (digestive enzyme supplement) 
and donepezil (cholinesterase inhibitor) 
These have only been addressed by single guidelines, 
with negative recommendations.
6,3
 
 
Vitamin C, piracetam (with risperidone), pentoxifylline 
(with risperidone), L-carnosine (dipeptide) and ketogenic 
diets 
There is limited/weak evidence for the above treatment 
presented mainly in the latest 2011 AHRQ guideline.
3
 The 
vitamin C evidence was reported in the 2007 AAP 
guideline document.
5
  
 
Autism is not an acceptable indication for hyperbaric 
oxygen treatment 
Some evidence for the effectiveness of hyperbaric 
oxygen was reported in the latest 2011 AHRQ guidelines.
3
 
They refer to the study by Rossignol DA et al in 2009.
40
 
This was a multicenter, randomized, double-blind, 
controlled trial reporting significant improvements in 
overall functioning, receptive language, social interaction, 
eye contact, and sensory/cognitive awareness. The study 
has been criticized for conflicts of interest and basic 
scientific issues.
41
 A review of this paper and three case 
series by the Undersea and Hyperbaric Medical Society 
(UHMS) again criticised the methodology of Rossignol's 
paper, suggested the need for replication, and could not 
recommend the routine treatment of autism using this 
modality.
12
 The UHMS indications are those upheld 
by the FDA.
42
 Rossignol's results could not be 
replicated by Granpeesheh's randomized, double-blind 
placebo controlled trial in 2010,
43
 nor could the 
effectiveness of this treatment be established by trials 
in 2011 by Jepson and Granpeesheh
44
 and Bent 
S, Bertoglio K, et al.
45
 In June 2011 the European 
Committee for Hyperbaric Medicine (ECHM) updated 
its 2010 recommended indications for hyperbaric 
oxygen by weighing the current clinical evidence: It 
has maintained that hyperbaric oxygen therapy is not 
indicated in autism.
11
 
Conclusion and recommendations 
It is felt that none of the evidence and 
recommendations found throughout the above 
literature review strongly support any of the 
biochemical approaches. Except for risperidone and 
aripiprazole none of the medical and biomedical 
medications, therapies or supplements are licensed for 
use in children with autism. 
In considering the application of biomedical 
treatments for autism the following recommendations 
are being forwarded: 
 
1. Melatonin may be considered in children with 
autism with sleep disturbance unresponsive to 
behavioural approaches alone.  
2. Omega-3 supplementation may be considered 
especially in autistic children who are hyperactive. 
3. All doctors caring for children with autism should 
be aware that these children may be on 
gluten/casein-free diets and be able to monitor 
possible nutritional deficiencies and their effects, 
and advise accordingly.  
4. Vitamin B6 and magnesium supplementation 
should be avoided.  
5. Iron, vitamin C, piracetam (as an add-on to 
risperidone), pentoxifylline (as an add-on to 
risperidone), ketogenic diets, L-carnosine are not 
recommended. 
6. Secretin, chelation, immunoglobulin, amantadine, 
antifungal/yeast therapies, naltrexone, 
dimethylglycine, vancomycin, digestive enzyme 
supplements and donepezil are strongly not 
recommended and should be discouraged. 
Chelation and immunoglobulin therapy are 
particularly not recommended in view of the risks 
associated with them. 
7. Hyperbaric oxygen therapy in autism is not 
effective and should not be recommended. 
8. Paediatricians, family doctors and other medical 
professionals should be aware of the various 
biomedical therapies which parents of children 
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with autism may be interested in, and have an 
understanding of the scientific evidence in favour of or 
against such approaches. 
 
References 
1.   Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Text Revision (DSM-IV-TR). American 
Psychiatric Association;  2000.  
2.   http://www.cdc.gov/ncbddd/autism/data.html Accessed 
25/1/12 
3.   Warren Z, Veenstra-VanderWeele J, Stone W, Bruzek JL, 
Nahmias AS, Foss-Feig JH, Jerome RN, et al. Therapies for 
Children With Autism Spectrum Disorders. Comparative 
Effectiveness Review No. 26. (Vanderbilt Evidence-based 
Practice Center) AHRQ Publication No. 11-EHC029-EF. 
Rockville, MD: Agency for Healthcare Research and Quality. 
April 2011. Available at: 
www.effectivehealthcare.ahrq.gov/reports/final.cfm. 
4.   New Zealand Ministries of Health and Education. New 
Zealand Autism Spectrum Disorder Guideline. Wellington: 
Ministry of Health. 2008. Available on-line at: 
www.moh.govt.nz/autismspectrumdisorder 
5.   Myers SM, Plauché Johnson C. Management of children 
with autism spectrum disorders. American Academy of 
Pediatrics guidance report. Pediatrics 2007;120;1162 
6. Scottish Intercollegiate Guidelines Network (SIGN). 
Assessment, diagnosis and clinical interventions for children 
and young people with autism spectrum disorders. A national 
clinical guideline.NHS Quality Improvement Scotland. July 
2007. Available on-line: http://www.sign.ac.uk 
7.   Fuentes-Biggi J. Ferrari-Arroyo MJ, Boada-Munoz L, 
Tourino-Aguilera E, Artigas-Pallares J, Belinchon-Carmona 
M, et al, Guide de bonnes pratiques dans le traitement des 
troubles du spectre autistique, Institut de Santé Carlos III, 
Ministère de la santé et de la consommation, Espagne. Revista 
de Neurologia. 2006; 43(7):425-438 French.   
8.   Roberts JM. A review of the research to identify the most 
effective models of best practice in the management of 
children with autism spectrum disorders. Centre for 
developmental disability studies. University of Sydney, 
Australia. Department of ageing, disability and home care. 
2004 
9.   Perry A, Condillac R. Evidence-based practices for children 
and adolescents with autism spectrum disorders. Review of 
the literature and practice guide. Children's Mental Health 
Ontario (CMHO). 2003 
10.   New York State Department of Health. Clinical practice 
guideline. Quick reference guide for parents. 
Autism/Pervasive developmental disorders. Assessment and 
intervention for young children (Age 0-3 years). 1999 
11.   Kot J, Mathieu D. Controversial issues in hyperbaric oxygen 
therapy: a European Committee for Hyperbaric Medicine 
Workshop. European Committee for Hyperbaric Medicine 
(ECHM). Diving Hyperb Med. 2011 Jun;41(2):101-4 
12.   Bennett M, Hart B. UHMS (Undersea and Hyperbaric 
Medical Society) Position paper. The treatment of autism 
spectrum disorder with hyperbaric oxygen therapy. Dec 5  
2009. Available online at:  http://membership.uhms.org. 
Accessed October 2012. 
13.   Akins RS, Angkustsiri K. Complementary and Alternative 
Medicine in Autism: An Evidence-Based Approach to 
Negotiating Safe and Efficacious Interventions with Families. 
The M.I.N.D. Institute. California. 17 July 2010. Available 
online at: 
http://www.sciencedirect.com/science/article/pii/S193372131
0000449 
14.   Adams J. Summary of biomedical treatments for autism. 
ARI Publication 40. April 2007. Available online at: 
http://autism.asu.edu 
15.   Hertz-Picciotto I, Green PG, Delwiche L, Hansen R, 
Walker C, Pessah IN. Blood mercury concentrations in 
CHARGE study children with and without autism. 
Environmental Health Perspectives vol 118 no 1 Jan 
2010. 
16.   Fitzpatrick M. Defeating Autism. A damaging delusion. 
Taylor & Francis e-Library, 2008. 
17.   DeNoon DJ. FDA warns against over-the-counter 
chelation. WebMD Health News. 2010 Oct 14.  
18.   Centers for Disease Control and Prevention (CDC). 
Deaths associated with hypocalcaemia from chelation 
therapy: Texas, Pennsylvania, and Oregon, 2003-
2005.Morbidity & Mortality Weekly Report. 
2006;55(8):204-207 
19.   WebMD. Chelation study for autism called off. Sept 
2008. Available online at: http://www.medscape.com 
20.   McPheeters ML quoted in Brauser D. Few effective 
treatment options for autism. Critical need for additional 
research into behavioural interventions. April 6 2011. 
Available online at: www.medscape.com 
21.   Rossignol D. How to Assess and Prioritize Treatments: 
Using Evidence-Based Medicine to Choose Effective 
Treatments. ARI 2010 conference. USA. October 2010. 
[Webcast]. Available online at: http://www.autism.com 
22.   Tordjman S, Anderson GM, Pichard N, Charbuy H, 
Touitou Y. Nocturnal excretion of 6-
sulphatoxymelatonin in children and adolescents with 
autistic disorder. Biol Psychiatry.2005;57 :134– 138 
23.   Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio, 
Sequeri P. Evidence of pineal endocrine hypofunction in 
autistic children. Neuro Endocrinol Lett. 2000;21:31–34 
24.   Phillips L, Appleton RE. Systematic review of 
melatonin treatment in children with 
neurodevelopmental disabilities and sleep impairment. 
Dev Med Child Neurol. 2004;46:771–775 
25.   Jan JE, Freeman RD. Melatonin therapy for circadian 
rhythm sleep disorders in children with multiple 
disabilities: what have we learned in the last decade? 
Dev Med Child Neurol.2004;46 :776– 782 
26.   Andersen IM, Kaczmarska J, McGrew SG, et al. 
Melatonin for insomnia in children with autism spectrum 
disorders. J Child Neurol. 2008 May; 23(5):482-485. 
27.   Appleton RE, Gringras P. Mends: the use of melatonin 
in children with neuro-developmental disorders and 
impaired sleep – a randomised, double-blind, placebo-
controlled, parallel trial. Arch Dis Child 2011;96:A1 
doi:10.1136/adc.2011.212563.1 
28.   British National Formulary for Children on-line. 
http://www.medicinescomplete.com/mc/bnfc/current 
Accessed 5/2/13 
29.   Sheldon SH. Pro-convulsant effects of oral melatonin in 
neurologically disabled children.  Lancet1998;351:125 
30.   Martindale on-line. 
http://www.medicinescomplete.com/mc/martindale/curre
nt. Last reviewed 2/9/2010. Accessed 5/2/13 
31.   Millward C, Ferriter M, Calver S, Connell-Jones G. 
Gluten- and casein-free diets for autistic spectrum 
disorder. Cochrane Database Syst Rev. 2008 Apr 
16;(2):CD003498 
32.   Mulloy A, Lang R, O'Reilly M,  Sigafoos J, Lancioni G, 
Rispoli M. Gluten-free and casein-free diets in the 
treatment of autism spectrum disorders: A systematic 
review. Research in Autism Spectrum Disorders (2009), 
doi:10.1016/j.rasd.2009.10.008 
  
 
Review Article 
 
 
 
 
Malta Medical Journal    Volume 25 Issue 01 2013                                                                                                              14 
 
 
 
33.  Whiteley P, Haracopos D, Knivsberg AM, Reichelt KL, 
Parlar S, Jacobsen J, et al. The ScanBrit Randomised 
Controlled, single-blind study of gluten and casein free 
dietary intervention for children with autism spectrum 
disorders. Nutr Neurosci. 2010 Apr;13(2):87-100  
34.   Hyman S, Stewart P A, Smith T, Foley J, Cain U, Peck R, et 
al. The gluten free and casein free (GFCF) diet: a double blind, 
placebo controlled challenge study [oral]. Presented at: 9th. 
International Meeting for Autism Research (IMFAR); May 
20-22, 2010; Philadelphia, PA. Abstract 140.007. 
35.   Weissman L, Bridgemohan C. Autism spectrum disorders in 
children and adolescents: Complimentary and alternative 
therapies. Official topic from UpToDate: Available online at: 
http://www.uptodate.com. Last update: 1 December 2011 
36.   Amminger GP, Berger GE, Schafer MR, et al. Omega-3 
fatty acids supplementation in children with autism: a double-
blind randomized, placebo-controlled pilot study. Biol 
Psychiatry. 2007 Feb 15;61(4):551-3 
37.   Bent S, Bostrom A. A pilot randomized controlled trial of 
omega-3 fatty acids for autism spectrum disorder. J Autism 
Dev Disord. 2011. 41:545-554 
38.    James S, Montgomery P, Williams K. Omega-3 fatty acids 
supplementation for autism spectrum disorders (ASD) 
Cochrane Database of Systematic Reviews. 
2011;(11)CD007992 
39.   Silva CD, D'Cruz DP. Pyridoxine toxicity courtesy of your 
local health food store. Ann Rheum Dis 2006; 65:1666 
40.  Rossignol DA, Rossignol LW, Smith S, Schneider C, 
Logerquist S, Usman A, et al. Hyperbaric treatment for 
children with autism: a multicenter, randomized, double-
blind, controlled trial. BMC Pediatr. 2009 Mar 13;9:21 
41.   Anderson P. Hyperbaric therapy may improve autism 
symptoms. Study sparks debate, concern, among 
neurologists. April 2009. Available online at:  
www.medscape.com 
42.   US Food and drug administration, FDA. Specific 
indications for use of  hyperbaric chambers Aug 2011. 
Available online at: 
http://www.accessdata.fda.gov/cdrh_docs/pdf10/K10283
1.pdf. Accessed 18/1/12 
43.   Granpeesheh D, Tarbox J, Dixon DR, Wilke AE, Allen 
M.S, Bradstreet JJ. Randomized trial of hyperbaric 
oxygen therapy for children with autism. Research in 
Autism Spectrum Disorders  Volume 4, Issue 2, April–
June 2010: 268–275 
44.  Jepson B, Granpeesheh D, Tarbox J, Olive ML, Stott C, 
Braud S, et al. Controlled evaluation of the effects of 
hyperbaric oxygen therapy on the behavior of 16 
children with autism spectrum disorders. Thoughtful 
House Center for Children, Austin, TX, USA. J Autism 
Dev Disord. 2011 May; 41(5):575-88. 
45.   Bent S, Bertoglio K, Ashwood P, Nemeth E, Hendren 
RL. Brief Report: Hyperbaric Oxygen Therapy (HBOT) 
in Children with Autism Spectrum Disorder: A Clinical 
Trial. J Autism Dev Disord. Department of Psychiatry, 
University of California, San Francisco, CA, USA 2011 
Aug 5. 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
